Market research
IPSC Century Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 393M
- P/E ratio
- Not available
- Analyst target
- 4.75
- Dividend yield
- Not available
- Beta
- 1.6
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US15673T1007
- Market cap
- 393M
- P/E ratio
- Not available
- Analyst target
- 4.75
- Dividend yield
- Not available
- Beta
- 1.6
About
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IPSC discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Other sector with a price to sales ratio of 0.0.
Based on the above factors, Century Therapeutics, Inc. Common Stock gets an overall score of 1/5.